Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Strengthens Presence in India with JMP Advisors18.6.2026 15:00:00 EEST | Press release
Andersen Global enters into a Collaboration Agreement with JMP Advisors in India, adding tax capabilities to its existing legal capabilities in the country. Providing advice across tax, regulatory and transaction matters, JMP Advisors serves domestic and multinational clients operating in complex and evolving business environments. The firm provides services spanning international and Indian domestic tax, transfer pricing, cross-border structuring, foreign investment advisory, transaction support, succession planning and regulatory matters. Its clients include multinational corporations, growing enterprises, private equity and venture capital-backed businesses, and high-net-worth individuals and families. “Our approach has always centered on delivering clear, actionable guidance that helps clients navigate complex situations and continue their business with a clear sense of direction,” said Jairaj Purandare, founder and chairman of JMP Advisors Private Limited. “Collaborating with Ande
IFCO Launches TRLLN, a Pioneering Tracking-as-a-Service Solution for Global Asset Visibility18.6.2026 13:55:00 EEST | Press release
IFCO, a global leader in reusable packaging solutions for the fresh food supply chain, is launching TRLLN (pronounced “trillion”), a standalone technology venture designed to help companies improve visibility across large, fast-moving asset networks. Unlike traditional tracking models that often require gates, scanners, or fixed hardware installations along the supply chain, TRLLN’s infrastructure-free approach allows companies to deploy asset tracking significantly faster and with less operational complexity. TRLLN’s platform addresses four core visibility questions across industries: where the asset is, whether it is in the right condition, whether it has reached the right destination, and what its full movement history shows. While use cases differ by sector, the technology can be applied across a wide range of industries. TRLLN brings proven asset tracking hardware and software technology to companies managing large networks of reusable and mobile assets, including pallets, contain
NIQ and Ogury Collaborate to Enhance Media Planning and Audience Strategy with GeoPurchase Insights18.6.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), the world’s leading consumer intelligence company, today announced a new collaboration with Ogury, the global AdTech company powered by Persona Intelligence. Through the collaboration, Ogury will integrate NIQ’s GeoPurchase data into its Persona Intelligence Engine, strengthening audience planning, media activation, and strategic insights for marketers. NIQ delivers world-leading retail intelligence, capturing actual purchase data at the product level across key retailers around the world. Through this collaboration, NIQ is providing GeoPurchase insights at scale across France, Germany, Spain, Italy, the UK, as well as the United States and Canada, bringing a new layer of real-world retail purchase behavior into Ogury’s Persona Intelligence Engine. Combined with Ogury’s audience-first data model—which brings together observed behaviours, declared intents, and deterministic signals—these insights help create rich, multi-dimensional personas informed by actual purchasing
Linvo Sets Sights on AI-Led Wealth Management, Opens AI Advisor Roles for 202618.6.2026 12:40:00 EEST | Press release
Linvo AG, a Zurich-based multi-family office and wealth management firm, today set out its vision for the year ahead, naming applied artificial intelligence as the centre of its strategy for 2026 and opening a new set of AI advisor roles to deliver it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618933521/en/ Linvo sets sights on AI-led wealth management, opens AI advisor roles for 2026 The firm sees the coming year as the point at which AI moves from a support tool to a core discipline within wealth management — shaping how portfolios are analysed, how clients are served, and how advisory teams spend their time. The new AI advisor roles are intended to anchor that shift inside the firm. "2026 is the year we stop treating AI as an add-on and start treating it as a discipline in its own right," said Alexander Kogan, Director at Linvo. "Hiring AI advisors is how we build that future deliberately, rather than leaving it t
Frost & Sullivan 2026 Technology Innovation Leadership Best Practices Recognition for Ohmium International18.6.2026 11:31:00 EEST | Press release
Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has received the 2026 Global Technology Innovation Leadership Recognition for Best Practices in the PEM electrolyzer and green hydrogen industry by Frost & Sullivan. This recognition highlights Ohmium's continued advancement of cutting-edge PEM technology into scalable, real-world hydrogen solutions that address critical energy and industrial challenges across global markets. Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition for Best Practices to organizations that demonstrate exceptional achievement in leveraging technology to drive market transformation and measurable business impact. The firm evaluates companies across two core dimensions: technology leverage and business impact. Ohmium excelled across both measures, demonstrating commitment to innovation, stage gate efficiency, commercialization, and applic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom